In the current issue of CHEST (see page 2021),
|
|
- Ezra Patrick
- 6 years ago
- Views:
Transcription
1 13 MacKinnon KL, Molnar Z, Lowe D. Use of microalbuminuria as a predictor of outcome in critically ill patients. Br J Anaesth 2000; 84: De Gaudio AR, Spina R. Glomerular permeability and trauma: a correlation between microalbuminuria and injury severity score. Crit Care Med 1999; 27: Fluoroquinolones for Respiratory Infections Too Valuable To Overuse In the current issue of CHEST (see page 2021), Guthrie has provided a broad and useful review of newer treatment options for the pathogens most commonly associated with both community-acquired pneumonia (CAP) and bronchitis, with a strong emphasis on the potential value of newer fluoroquinolones for empiric treatment. Guthrie discusses older fluoroquinolones such as ciprofloxacin (Bayer Pharmaceuticals; West Haven, CT) and levofloxacin (Ortho-McNeil Pharmaceutical; Raritan, NJ), and as newer fluoroquinolones moxifloxacin (Bayer Pharmaceuticals), gatifloxacin (Bristol-Myers Squibb; New York, NY), and trovafloxacin (Pfizer; New York, NY). He acknowledges his support by two of these pharmaceutical companies (Bayer Pharmaceuticals and Bristol-Myers Squibb). Many share his view (as I do) that currently available fluoroquinolones provide excellent coverage for most treatable respiratory pathogens, including atypical and more readily cultured pathogens. Excellent absorption and minimal toxicity permit comparable oral and IV therapy for the treatment of serious infections, which sets these drugs apart from most -lactam drugs and the older macrolide erythromycin. Either newer macrolide azithromycin and older broad-spectrum doxycycline can be comparably dosed orally and IV, and both cover atypical pathogens. However, fluoroquinolones variably offer greater Gram-negative coverage, greater efficacy with highly resistant pneumococci, and/or greater anaerobic coverage, providing advantages for treating selected patients when used as monotherapy. Rapid conversion from IV to oral therapy reduces the cost of hospitalization by reducing drug costs and, potentially, the length of stays in the hospital. As such, fluoroquinolones combine exceptional efficacy with cost-effectiveness. Therefore, it is not surprising that some medical systems have adopted fluoroquinolones as empiric therapy in clinical pathways for the treatment of CAP. 1,2 Efficacy and tolerance data support their use among outpatients with exacerbations of chronic bronchitis as well. 3 Some of the older, more established fluoroquinolones, including ciprofloxacin and levofloxacin, have proven remarkably safe over time at higher doses than usually are prescribed. 4 Ciprofloxacin at 750 mg bid appears to be safe and at least comparable in effectiveness for the outpatient treatment of acute bronchitis and pneumonia when compared to other commonly utilized drugs. 5,6 High doses of ciprofloxacin were recommended by the Infectious Diseases Society of America (IDSA) in their CAP guidelines when Pseudomonas aeruginosa infection is considered. 7 Very high doses of ciprofloxacin and levofloxacin have successfully treated persistent osteomyelitis 8 and may be useful for treatment of empyema where local concentrations exceed serum concentrations. 9,10 Higher tissue concentrations of levofloxacin and newer fluoroquinolones in sites of inflammation provide theoretical advantages for the treatment of empyema or infections of other poorly vascularized spaces, but clinical trials of these conditions are lacking. Two sets of guidelines for the treatment of CAP, one a combined effort of the Canadian Infectious Disease Society/Canadian Thoracic Society (CIDS/ CTS) 11 and the other by the IDSA, 12 were recently published simultaneously. Readers are encouraged to seek copies of these guidelines and the accompanying editorial, 13 which favor fluoroquinolones but somewhat less strongly than presented in the article by Guthrie. The guidelines generally favor the primary or secondary consideration of fluoroquinolones in the initial empiric treatment of patients who have the most complicated cases of CAP and are admitted to the hospital, while generally favoring macrolides or doxycycline for the treatment of less sick outpatients, at least among those without special needs for fluoroquinolones. These recommendations are summarized in tables in each of the two studies cited 11,12 and are compared here in Table 1. Importantly, these guidelines presume that sputum and blood cultures are collected routinely and will lead to a change to an antibiotic with narrower coverage rather than the persistent use of fluoroquinolones in hospitalized patients. However, clinicians are often reluctant to withdraw what appears to be effective therapy in very sick patients. Furthermore, cultures frequently are not sufficiently diagnostic, 14 fueling controversy regarding the value of routine sputum cultures. Therefore, because most patients with CAP improve in the hospital on empiric therapy, the initial therapy is continued in most patients when feasible. The conditions of patients with acute exacerbations of chronic bronchitis associated with dyspnea and/or a change in sputum character generally also improve during antibiotic therapy, 15 leading to the CHEST / 120 / 6/ DECEMBER,
2 Table 1 Comparison of Recent Guidelines for Empiric Initial Therapy of CAP* Variables Drugs Recommended Modifying Factors IDSA (Bartlett et al 12 ) Outpatient Hospitalized ward ICU Doxycycline, macrolide, or fluoroquinolone (no distinction) Cefalosporin (macrolide or fluoroquinolone) or; -lactam/ -lactamase inhibitor macrolide; or; fluoroquinolone alone (Cefalosporin or -lactam/ -lactamase inhibitor) (macrolide or fluoroquinolone) Older patients: many prefer fluoroquinolone Underlying disease: many prefer fluoroquinolone Prevalence high PCN resistance: consider fluoroquinolone Prior lung disease: (pseudomonal -lactam [ -lactamase inhibitor] or carbapenem) fluoroquinolone (high-dose ciprofloxacin) -lactam allergy: fluoroquinolone clindamycin Suspect aspiration: fluoroquinolone (clindamycin, metronidazole, or -lactam/ -lactamase inhibitor) CIDS/CTS (Mandell et al 11 ) Outpatient 1st choice macrolide, or 2nd choice doxycycline COPD: 1st choice newer macrolide, or 2nd choice doxycycline COPD recent antibiotic or steroid: 1st choice respiratory fluoroquinolone (eg, levofloxacin or newer generation), or 2nd choices (amoxicillin/clavulonate macrolide), or 2nd-generation cephalosporin macrolide Suspect aspiration: 1st choice amoxicillin/clavulonate macrolide or 2nd choice respiratory fluoroquinolone (clindamycin or metronidazole) Nursing home: respiratory fluoroquinolone Hospitalized ward 1st choice IV respiratory fluoroquinolone or 2nd choice (2nd-, 3rd-, or 4th-generation cephalosporin macrolide) ICU * with or without; PCN penicillin. 1st choice respiratory fluoroquinolone (cefotaxime, ceftriaxone, or -lactam/ -lactamase inhibitor) or 2nd choice IV macrolide (cefotaxime, ceftriaxone, or -lactam/ -lactamase inhibitor) Pseudomonas suspected: 1st choice antipseudomonal fluoroquinolone (eg, ciprofloxacin) (antipseudomonal -lactam or aminoglycoside) or 2nd choice triple therapy with antipseudomonal -lactam (eg, ceftazidime, piperacillin-tazobactam, imipenem, or meropenem) aminoglycoside macrolide continuation of empiric therapy when these patients are admitted to hospital as well. A wide variety of drugs have been employed, and the article by Guthrie points to the potential efficacy of fluoroquinolones in this setting as well. As data continue to demonstrate efficacy, safety, and short-term overall cost reduction in treating respiratory infections with fluoroquinolones, their use is increasing. Unfortunately, bacteria that are resistant to these agents are also increasing. 16,17 Widespread use of fluoroquinolones among hospitalized patients has induced more frequent resistance among nosocomial pathogens. 18,19 Surveillance data from two teaching hospitals in this community have demonstrated an increase in the isolation of resistant organisms, particularly among nosocomial pathogens. Ciprofloxacin-resistant Pseudomonas isolates in the ICU rose from 30% in 1998 to 43% in 1999; among outpatients, isolates rose from 17% in 1998 to 25% in 1999 (Lauri Thrup, MD; personal communication; May 9, 2001). While resistance among the most common community-acquired pathogens remains infrequent in the United States, 20,21 resistance is beginning to appear among pneumococci in Canada. 22 Recurrent use among patients in the community is likely to promote resistance among outpatients as well, particularly among patients with chronic bronchitis. 3,23 25 Therefore, it would seem prudent to reconsider where and how to potentially limit the overuse of this valuable new class of drugs while still capitalizing on the opportunities to utilize their unique strengths. A number of approaches could be offered. The classic approach recommended by the IDSA and CIDS/ CTS 11,12 focuses on aggressive sampling, with cultures and sensitivities permitting the derecruitment of some patients from the long list of patients who are receiving fluoroquinolones in hospitals. Two 1772 Editorials
3 alternative considerations are suggested here that may help to diminish the emergence of resistant strains, focused first on diminishing their use among inpatients who are expected to have a prolonged stay in the hospital, and second on outpatients who experience chronic, recurrent infections. Admittedly, these alternative strategies appear to conflict with recent North American recommendations, 11,12 which generally favor the empiric use of fluoroquinolones among patients with CAP who are very sick or have prior lung disease. First, among hospitalized patients it would seem wise to try to avoid placing those anticipated to have a long hospital course on fluoroquinolones unless alternative regimens could not provide comparable coverage. This effort would seem most important for patients admitted to the ICU, where resistant strains emerge most notoriously, particularly among intubated patients. Factors that argue for choosing a fluoroquinolone include intolerance to other drugs, poor clinical responses to other drugs, or isolated organisms demonstrating resistance to other drugs in vitro. However, alternative regimens should be considered for most other patients. While many alternatives to fluoroquinolones could be offered, the review by Guthrie points out the importance of initial empiric coverage of both atypical and typical pathogens with CAP. Both the IDSA and CIDS/CTS guidelines outlined in Table 1 provide alternative regimens, even if not the favored regimen. For very sick patients who are expected to have a prolonged hospital stay, consider a two-drug regimen combining a -lactam with or without a -lactamase inhibitor (eg, a second-generation or third-generation cephalosporin, ampicillin/sulbactam, or high doses of piperacillin/tazobactam to enhance coverage of Pseudomonas) for broad coverage of typical organisms, plus a second drug for atypical pathogens (eg, a macrolide or doxycycline). These two-drug regimens will provide broad and effective empiric coverage for most patients. The obvious exceptions would be those patients already not responding to therapy with these drugs or patients who are intolerant to these drugs. Of note, the use of doxycycline for atypical coverage in hospitalized patients is not suggested in either of the recent guidelines cited. 11,12 However, a study 26 of patients hospitalized with CAP, which excluded ICU patients, found monotherapy with IV doxycycline at 100 mg q12h (converted to oral administration for outpatient continuation) provided short-term outcomes that were at least as good as off-pathway, individual, physician-directed antibiotic selection, with a markedly reduced overall cost. Monotherapy with a high dose (ie, 500 mg qd) of azithromycin also was found to be as effective and better tolerated than a combination therapy of erythromycin and a cephalosporin in hospitalized patients, again excluding ICU patients. 27 These data do not provide an adequate basis for the use of monotherapy with either agent among patients sick enough to be admitted to the ICU. However, their efficacy as monotherapy for less sick patients supports the consideration of either for atypical coverage when combined with a -lactam therapy with or without a -lactamase inhibitor in ICU patients. Most hospitalized patients will respond to these alternative empiric regimens, reducing the selection pressure for the emergence of fluoroquinolone resistance in the hospital. These alternative regimens could be applied to all patients who are sick enough to need hospitalization for CAP. However, patients who are likely to tolerate discharge from the hospital within a couple of days of receiving an effective oral regimen provide good candidates for monotherapy with a fluoroquinolone. 1,2 This may facilitate conversion to outpatient therapy, reducing the risk of hospital readmission that is associated with a change in therapy, while reducing the time for the emergence of resistant strains in hospitals. As noted above, the available data suggest that monotherapy with either azithromycin 27 or doxycycline 26 also may prove to be effective for these patients, but the data are fewer. More clinical trials comparing outcomes of patients with CAP are needed, comparing monotherapy with each of these three drug classes (ie, fluoroquinolones, azithromycin, or doxycycline) in patients who are less sick, and as two-drug regimens combined with a very broad-spectrum bactericidal agent in ICU patients. Unfortunately, there is no economic incentive for a pharmaceutical company to study doxycycline in either setting. For patients admitted to the hospital with acute bronchitis or purulent acute exacerbations of chronic bronchitis, a number of regimens may be effective. However, the published data primarily reflect studies of outpatients. In a meta-analysis of otherwise healthy individuals, erythromycin, doxycycline, or trimethoprim-sulfamethoxazole alone was recommended as a cost-effective treatment of acute bronchitis. 28 Few of these patients are sick enough to be admitted to the hospital. In an analysis of costeffective management of acute exacerbations of chronic bronchitis, drugs were grouped as first line (ie, amoxicillin, trimethoprim-sulfamethoxazole, tetracyclines, and erythromycin), second line (cephradine, cefuroxime, cefaclor, and cefprozil) or third line (amoxicillin-clavulanate, azithromycin, and ciprofloxacin) for analyses. 29 Trends toward better outcomes with low overall cost favored the third-line drugs in this analysis. While additional direct com- CHEST / 120 / 6/ DECEMBER,
4 parisons of classes of drugs would be more valuable, the available data do not demonstrate the clear superiority of the fluoroquinolones in this setting. As with CAP patients, these drugs may be better reserved for patients who have not responded to other antibiotics, who are known to have organisms resistant to other antibiotics, or who cannot tolerate other antibiotics, with a focus again on reducing the selection pressure for the emergence of resistant strains. The second area of potential focus is outpatient therapy. A number of reasonable alternative oral agents to treat both CAP and bronchitis are outlined above. The use of fluoroquinolones in this setting could be reasonably reserved for those patients who have not responded to treatment with other agents, who have organisms isolated that are resistant to other antibiotics, or who are intolerant of other antibiotics. This approach should decrease the pressure selecting fluoroquinolone-resistant strains among patients with recurrent exacerbations of chronic bronchitis or bronchiectasis. Fluoroquinolones may be useful for the treatment of patients who are potentially sick enough to be admitted to a hospital but who prefer a trial of outpatient therapy. This approach again would reduce the selection pressure in hospitals where resistant organisms are more readily shared. When a fluoroquinolone is selected for the treatment of CAP or bronchitis, differences in these agents merit some consideration, as is suggested by Guthrie. The newer fluoroquinolones provide more enhanced coverage for Gram-positive and atypical pathogens than ciprofloxacin, while the older ciprofloxacin provides greater efficacy for Pseudomonas species. 30 However, it is important to note that levofloxacin also provides very good coverage for Gram-positive and atypical infections, while maintaining very good coverage for Pseudomonas species. 31,32 Therefore, ciprofloxacin remains the fluoroquinolone of choice for patients with known Pseudomonas infections, particularly at higher doses (eg, 750 mg bid). Levofloxacin provides a useful empiric alternative to ciprofloxacin for patients in whom the role of P aeruginosa is unclear and for whom broader coverage for atypical and Grampositive pathogens also is desired. 33 Newer fluoroquinolones lose activity against Pseudomonas but increase activity against atypical, Gram-positive, and anaerobic pathogens. Unfortunately, the treatment of acute purulent exacerbations of chronic bronchitis with a fluoroquinolone can induce resistant isolates. 3 Therefore, one must remain cautious regarding the use of fluoroquinolones among patients who are likely to have recurrent infections. In summary, the excellent safety and efficacy of fluoroquinolones in respiratory infections, as detailed by Guthrie, has led to the markedly accelerated use of these drugs. As with any heavily utilized antibiotic class, resistance is expected also to accelerate. Because this class appears to be so valuable for serious, persistent infections, particularly among outpatients, it would seem prudent to look for opportunities to limit the overuse of these drugs. Hopefully, these and other strategies will emerge before the utility of fluoroquinolones is too severely compromised. James H. Williams, Jr, MD, FCCP Orange, CA Dr. Williams is Adjunct Professor of Medicine, Internal Medicine, Pulmonary, and Critical Care, University of California, Irvine. Correspondence to: James H. Williams, Jr, MD, FCCP, Internal Medicine, Pulmonary, and Critical Care, University of California, Irvine, 101 City Drive South, Orange, CA 92868; j2willia@uci.edu References 1 Siegel RE. Strategies for early discharge of the hospitalized patient with community-acquired pneumonia. Clin Chest Med 1999; 20: Palmer CS, Zhan C, Elixhauser A, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 2000; 22: Davies BI, Maesen FP. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J Antimicrob Chemother 1999; 43(suppl): Modai J. High-dose intravenous fluoroquinolones in the treatment of severe infections. J Chemother 1999; 11: Cazzola M, Vinciguerra A, Beghi GF, et al. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J Chemother 1995; 7: Anzueto A, Niederman MS, Tillotson GS. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin Ther 1998; 20: Bartlett JG, Breiman RF, Mandell LA, et al. Communityacquired pneumonia in adults: guidelines for management; the Infectious Diseases Society of America. Clin Infect Dis 1998; 26: Greenberg RN, Newman MT, Shariaty S, et al. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother 2000; 44: Joseph J, Vaughan LM, Basran GS. Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. Ann Pharmacother 1994; 28: McLaughlin RL. Managing the nonsurgical candidate with an empyema related to community-acquired lobar pneumonia. Heart Lung 2000; 29: Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society; The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31: Editorials
5 12 Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America. Clin Infect Dis 2000; 31: Mandell LA. Guidelines for community-acquired pneumonia: a tale of 2 countries. Clin Infect Dis 2000; 31: Theerthakarai R, El-Halees W, Ismail M, et al. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest 2001; 119: Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15: Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother 2000; 44: Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000; 30: Manhold C, von Rolbicki U, Brase R, et al. Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study. Intensive Care Med 1998; 24: Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries: French and Portuguese ICU Study Groups. JAMA 1999; 281: Biedenbach DJ, Jones RN. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America). Diagn Microbiol Infect Dis 2000; 36: Klugman KP, Gootz TD. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1997; 39(suppl): Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: Vila J, Ruiz J, Sanchez F, et al. Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrob Agents Chemother 1999; 43: Jalal S, Ciofu O, Hoiby N, et al. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000; 44: Speciale A, Musumeci R, Blandino G, et al. Molecular mechanisms of resistance in Pseudomonas aeruginosa to fluoroquinolones. Int J Antimicrob Agents 2000; 14: Ailani RK, Agastya G, Mukunda BN, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999; 159: Vergis EN, Indorf A, File TM Jr, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160: Bent S, Saint S, Vittinghoff E, et al. Antibiotics in acute bronchitis: a meta-analysis. Am J Med 1999; 107: Destache CJ, Dewan N, O Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43(suppl): Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000; 14: North DS, Fish DN, Redington JJ. Levofloxacin, a secondgeneration fluoroquinolone. Pharmacotherapy 1998; 18: Segatore B, Setacci D, Perilli M, et al. Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa. Int J Antimicrob Agents 2000; 13: Casellas JM, Gilardoni M, Tome G, et al. Comparative invitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. J Antimicrob Chemother 1999; 43(suppl):37 42 Forthcoming Articles in CHEST Atrial Mechanical Performance After Internal and External Cardioversion of Atrial Fibrillation: An Echocardiographic Study Lehmann and colleagues Editorial comment by Dunn and coauthors Costs of Occupational COPD and Asthma Leigh and colleagues Hospice Care for Patients With Advanced Lung Disease Abrahm and Hansen-Flaschen Editorial comment by Peter B. Terry Respiratory Symptoms and Nocturnal Gastroesophageal Reflux: A Population-Based Study of Young Adults in Three European Countries Gislason and coworkers Editorial comment by William C. Orr Early Treatment of Stage II Sarcoidosis Improves 5-Year Pulmonary Function Pietinalho and colleagues Editorial comment by Albert Miller CHEST / 120 / 6/ DECEMBER,
Measure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only
Last Updated: Version 4.4a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Collected For: CMS Voluntary
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationBai-Yi Chen MD. FCCP
Treatment strategies for hospitalized versus nonhospitalized CAP patients: Asian perspective Bai-Yi Chen MD. FCCP Professor of Medicine Division of Infectious Disease, Infection Control Team The First
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationAntimicrobial Stewardship in Ambulatory Care
Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationIMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationObjectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationCompliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings
Compliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings Jasmanda H. Wu, Ph.D., 1 David H. Howard, Ph.D., 2 John E. McGowan, Jr.,
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More information10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally
Low: not well absorbed PO agent not for serious infection nitrofurantoin Good: [blood and tissue] < than if given IV [Therapeutic] in excess of [effective] eg. cephalexin High: > 90% absorption orally
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationGuidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia*
special reports Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia* Thomas M. File, Jr, MD, FCCP; Javier Garau, MD; Francesco Blasi, MD, PhD; Christian Chidiac, MD; Keith
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationHospital-acquired pneumonia (HAP) is the second
Guidelines and Critical Pathways for Severe Hospital-Acquired Pneumonia* Stanley Fiel, MD, FCCP Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationNational Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4606 4610 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4606 4610.2004 Copyright 2004, American Society for Microbiology. All Rights
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful Measure Area: Appropriate Use of Healthcare 2019 COLLECTION
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationQuality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction
Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationAntibiotics Use And Concordance To Guidelines For Patients Hospitalized With Community Acquired Pneumonia (CAP)
Antibiotics Use And Concordance To Guidelines For Patients Hospitalized With Community Acquired Pneumonia (CAP) SF Teoh 1, Samsinah Hussain 1, CK Liam 2 1 Departments of Pharmacy, Faculty of Medicine,
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationLevofloxacin and moxifloxacin resistant Haemophilus influenzae in a patient with common variable immunodeficiency (CVID): a case report
46 Case Report Levofloxacin and moxifloxacin resistant Haemophilus influenzae in a patient with common variable immunodeficiency (CVID): a case report CT Hapuarachchi 1, GK Karunaratne 2, NR de Silva 3,
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationPneumonia. Community Acquired Pneumonia (CAP): definition. At least 2 new symptoms
Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Community Acquired Pneumonia (CAP): definition At least 2 new symptoms Fever or hypothermia Cough Rigors
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationMore than 4 million episodes of communityacquired
Overview of Recent Guidelines for the Management of Community-Acquired Pneumonia David C. Rhew, MD More than 4 million episodes of communityacquired pneumonia (CAP) occur each year in the United States,
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationDoxycycline for strep pneumonia
Doxycycline for strep pneumonia Antibiotic Levofloxacin (Levaquin) 750 mg, 500 mg for the treatment of respiratory, skin, and urinary tract infections, user reviews and ratings. 14-12-1995 John G. Bartlett,
More informationAntimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley
Antimicrobial Update Stewardship in Primary Care Clare Colligan Antimicrobial Pharmacist NHS Forth Valley Setting the Scene! Consequences of Antibiotic Use? Resistance For an individual patient with
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationCommunity Acquired Pneumonia. Epidemiology: Acute Lower Respiratory Tract Infections. Community Acquired Pneumonia (CAP) Outline
Community Acquired Pneumonia (CAP) Outline Lisa G. Winston, MD University of California, San Francisco Zuckerberg San Francisco General Epidemiology Diagnosis Microbiology Risk stratification Treatment
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationORIGINAL INVESTIGATION. Antibiotic Therapy for Ambulatory Patients With Community-Acquired Pneumonia in an Emergency Department Setting
Antibiotic Therapy for Ambulatory Patients With Community-Acquired Pneumonia in an Emergency Department Setting Christine Malcolm, BSc; Thomas J. Marrie, MD ORIGINAL INVESTIGATION Background: Little attention
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationWhat is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa.
Pneumonia What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa www.netmedicine.com/xray/xr.htm Definition acute infectious disease, etiology usually
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationHigh Risk Emergency Medicine. Antibiotic Pitfalls
High Risk Emergency Medicine Antibiotic Pitfalls David, MD MS Assistant Professor Department of Emergency Medicine University of California, San Francisco I. Antibiotic Resistance Development of resistance
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationRational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationAntibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen
Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationLack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014
H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 213 Second and Third Quarters
More informationStudy of Fluoroquinolone Usage Sensitivity and Resistance Patterns
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2013, 5 (5):195-199 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationCommunity-acquired pneumonia (CAP) is a common,
OUTCOMES IN PRACTICE A Tool for Appropriate Antibiotic Use in the Management of Community-Acquired Pneumonia Alan B. Bernstein, MD, MPH, Thomas M. File Jr, MD, and Jeffrey S. Markowitz, DrPH Community-acquired
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationORIGINAL INVESTIGATION. Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia
ORIGINAL INVESTIGATION Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia Reba K. Ailani, MD; Gautami Agastya, MD; Rajesh K. Ailani, MD; Beejadi N. Mukunda,
More informationAntibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections
...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationReport on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli"
Preserving the Power of Antibiotics Report on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli" Held on Thursday, September 30, 2004 in Boston, MA Preceding
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationCommunity-Acquired Pneumonia. Community-Acquired Pneumonia. Community Acquired Pneumonia (CAP): definition
Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Community-Acquired Pneumonia Talk will focus on adults Guideline for healthy infants
More information